The FDA has approved Provention’s BLA for intravenous antibody TZIELD to delay stage 3 type 1 diabetes, making it the first disease-modifying drug indicated to slow disease progression.
https://www.pharmalive.com/wp-content/uploads/2021/08/Ipsen-Voluntarily-Withdraws-FDA-Submission-for-FOP-Drug-BioSpace-8-13-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-18 09:01:242022-11-18 09:02:36FDA greenlights Provention’s TZIELD as first drug to delay advanced T1D
